Search

Displaying results 5251 - 5260 of 10000 in total
  1. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … of limbic system with respect to anxiety and depression.

  2. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  3. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  4. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine. … , and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells.

  5. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. … The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  6. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  7. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … [A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  8. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus. … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).

  9. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen. … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB.

  10. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.